Liberty Health Sciences (OTCQX:LHSIF) announces an update in response to COVID-19.
All Liberty dispensaries across Florida remain open during regularly scheduled business hours.
In an effort to satisfy increase in the demand for its medical cannabis products, Liberty has streamlined the following processes: easy online ordering; text message staging notifications; free home delivery (where applicable); curbside pickup and extended operation hours.
The company expects to open at least three new stores by the end of Q1 2021.
Thinly traded nano cap aTyr Pharma (NASDAQ:LIFE) jumps 19% premarket on increased volume on the heels of the FDA’s sign-off on a Phase 2 clinical trial evaluating lead candidate ATYR1923 in COVID-19 patients with severe respiratory complications.
ATYR1923 is a fusion protein designed to downregulate T cell responses thereby dampening inflammatory cytokine (protein) and chemokine signaling associated with severe COVID-19 cases. The company says it has also shown to improve lung function, in addition to reducing inflammation and fibrosis, in animal models of immune-mediated acute lung injury.
The FDA has approved the emergency use of LabCorp’s (NYSE:LH) Pixel COVID-19 test home collection kit enabling the collection of nasal swabs at home.
Healthcare workers and first responders will have initial priority.
Shares up 3% premarket on light volume.
Cara Therapeutics (NASDAQ:CARA) and licensee Vifor Fresenius Medical Care Renal Pharma announce positive results from a Phase 3 clinical trial, KALM-2, evaluating Korsuva (CR845/difelikefalin) Injection in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) (itchy skin), a condition affecting ~40% of dialysis patients.
The study met the primary endpoint of a statistically significant proportion of treated patients achieving at least a three-point improvement from baseline in a scale called WI-NRS score at week 12 versus placebo. Specifically, 54% of patients receiving Korsuva met the criterion, compared to 42% for control (p=0.02).
The secondary endpoint of the proportion of treated patients achieving at least a four-point improvement in WI-NRS score was also met but another, itch-related quality of life measures, was not.
Korsuva’s safety profile was similar to placebo.
An earlier Phase 3, KALM-1, was also successful (reported in May 2019).
Marketing applications will be filed in the U.S. and Europe in H2.
Cara management will host a conference call today at 8:30 am ET to discuss the results.
The FDA has approved Roche’s (OTCQX:RHHBY) cobas HPV test for use on its fully automated, high-throughput cobas 6800/8800 systems.
The molecular diagnostic test identifies women at risk of cervical cancer by detecting the presence of high-risk human papillomavirus (HPV) DNA in cervical samples.
